H.C. Wainwright raised the firm’s price target on Olema Oncology to $15 from $12 and keeps a Buy rating on the shares post the Q4 results. A restructuring plan is in place to focus on OP-1250 and extend the company’s cash runway into 2025, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on OLMA:
- Olema Oncology reports Q4 EPS (65c), consensus (65c)
- Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference
- Olema Oncology initiated with an Outperform at Credit Suisse